Indaptus Therapeutics is trading 9.78% down now at $1.20 after no clear company-specific catalyst emerged in the August 6, 2026 news search.
- Recent coverage describes speculative activity in the thinly traded biotechnology stock.
- Available company news is dated earlier and does not directly explain the decline.
- Broader indexes are mixed, so the current move remains unexplained rather than clearly tied to global sentiment.